SUMMARY Five babies who presented with supraventricular tachycardia were treated with verapamil intravenously. All developed severe hypotension and two died. Verapamil should not be used in the initial management of supraventricular tachycardia in neonates.
Verapamil is commonly used to treat supraventricular tachycardia in children.' Adverse effects of the drug in infants have been reported2 but the dangers are still not widely appreciated.
Case reports
Four boys and a girl with a mean age of 2-6 weeks (range 2-4 weeks) were all born at term after uneventful pregnancies and deliveries. Their mean birth weight was 3170 g (range 2810-3830 g), and they had no neonatal problems until presentation. CASE 
1
A baby girl developed a supraventricular tachycardia of 300 beats/minute with cardiac failure. She was given verapamil 0-3 mg/kg intravenously and five minutes later reverted to sinus rhythm. One hour later she collapsed with a severe bradycardia and despite vigorous resuscitation including administration of calcium gluconate, adrenaline, and dopamine she died. At necropsy the heart was normal. CASE Verapamil given intravenously has been advocated as the best drug for the treatment of supraventricular tachycardia.' Its side effects, however, (including hypotension and pronounced bradycardia) are well known,3 and have been reported in infants.2
Our experience includes two babies who died in the neonatal period and three who made stormy recoveries after developing severe hypotension. Two of these babies received only a small dose of verapamil (0.1 mg/kg).
Calcium gluconate is recommended for the treatment of the haemodynamic complications of verapamil administration.3 The response to calcium gluconate treatment, however, varies and it is not always successful.4 Calcium chloride may be more effective than calcium gluconate and this should be available when verapamil is given.5
The combination of verapamil and propranolol has unpredictable effects on the myocardium. Studies in adults have shown that it is safe if the left ventricle is contracting well but its use in those with impaired contractility is not recommended.6 These drugs have been used sequentially in the management of resistant supraventricular tachycardia in childhood. Our experience in case 3 shows that even when the interval between their administration is greater than the half life of verapamil, severe myocardial depression can still occur. Case 5 also illustrates that this combination can have disastrous consequences even if there is no impairment of myocardial contractility.
We recommend that verapamil should not be used in the initial treatment of supraventricular tachycardia in neonates and emphasise the dangers of the combination of propranolol and verapamil even if the myocardium is normal and there is a prolonged interval between doses. Synchronised or unsynchronised direct current cardioversion is perhaps the safest method of restoring sinus rhythm, which can then be maintained by digoxin. 
